Abstract
AbstractDifficulties in the formulation of griseofulvin tablets are reviewed. A number of griseofulvin direct compression, pre-compression and polyvinylpyrrolidone granulated tablet formulation have been successfully produced and evaluated, in all cases a mixture of dicalcium phosphate dihydrate and calcium phosphato-carbonate complex was used as tablet matrix. Attempts to use other direct compression tablet matrices proved unsuccessful. The tablets produced have been compared with two commercially available products and the data obtained indicated that the formulations developed in this study have potential for further exploitation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
